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ApoptosisTransgenic expression of the α7 integrin can ameliorate muscle pathology in a mouse model of Duchenne
muscular dystrophy (mdx/utr−/−) and thus can compensate for the loss of dystrophin in diseasedmice. In spite
of the beneﬁcial effects of the α7 integrin in protecting mice from dystrophy, identiﬁcation of molecular
signaling events responsible for these changes remains to be established. The purpose of this study was to
determine a role for signaling in the amelioration ofmuscular dystrophy byα7 integrin. Activation of PI3K, ILK,
AKT, mTOR, p70S6K, BAD, ERK, and p38 was measured in the muscle from wild type (WT), mdx/utr−/− and
α7BX2-mdx/utr−/− mice using in vitro activity assays or phosphospeciﬁc antibodies and western blotting.
Signiﬁcant increases in PI3K activity (47%), ILK activity (2.0-fold), mTOR (Ser2448) (57%), p70S6K (Thr389)
(11.7-fold), and ERK (Thr202/Tyr204) (66%) were demonstrated in dystrophic mdx/utr−/−muscle compared
to WT. A signiﬁcant decrease in p38 phosphorylation (2.9-fold) was also observed. Although most of these
signaling eventswere similar in dystrophicmdx/utr−/−mice overexpressing theα7 integrin, theAKT (Ser473):
AKT ratio (2-fold vs. WT) and p70S6K phosphorylation (18-fold vs. WT) were higher in α7BX2-mdx/utr−/−
compared tomdx/utr−/−mice. In addition, increased phosphorylation of BAD Serine 112may contribute to the
signiﬁcant reduction in TUNEL+ cells observed in α7BX2-mdx/utr−/− mice. We conclude that the α7β1
integrin confers a protective effect in dystrophicmuscle through the activation of the ILK, AKT, p70S6K andBAD
signaling to promote muscle cell survival.nced Science and Technology,
USA. Tel.: +1 217 244 1459;
t).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Duchenne muscular dystrophy (DMD) is caused by mutations in
the dystrophin gene resulting in the absence of the dystrophin protein
[1,2]. Dystrophin is a key component of a macromolecular complex
that links the cell cytoskeleton to laminin in the extracellular matrix
[3–5]. The lack of dystrophin in DMD patients results in severe
progressive muscle wasting. Patients are usually conﬁned to a
wheelchair in their early teens and death from cardiopulmonary
failure often occurs in their early twenties. In contrast, mdx mice, a
mousemodel for DMD, showmildmuscle pathology and live a normal
life span [2,6]. The muscles ofmdxmice show increased expression of
utrophin, a homologue of dystrophin normally found at neuromus-
cular and myotendinous junctions in the adult. In mdxmice, utrophinis localized around the sarcolemma suggesting that it may partially
compensate for the absence of dystrophin [7]. Mdx/utr−/− mice,
which lack both dystrophin and utrophin, develop severe pathology
that closely resembles that seen in DMD and die at 4–20 weeks of age
[8,9].
Both mdx mice and DMD patients have elevated levels of α7β1
integrin, a heterodimeric transmembrane receptor found in skeletal
and cardiac muscle that also links laminin in the extracellular matrix
to the cell cytoskeleton [10]. This led us to hypothesize that the
dystrophin and integrin linkage systemsmay be complementary, such
that in the absence of dystrophin, the level of α7β1 integrin is
increased. The results led us to question whether further increasing
integrin levels in the absence of the dystrophin linkage system could
prevent the development of muscle disease. This hypothesis was
conﬁrmed in transgenic mdx/utr−/− mice in which expression of the
α7BX2 integrin chain was further increased in skeletal muscle. An
additional two-fold increase in α7β1 integrin protein reduced the
development of muscular dystrophy and increased longevity of the
α7BX2-mdx/utr−/− transgenic mice three-fold [11].
The mechanism by which the mdx/utr−/− mice were rescued by
increased α7β1 integrin is unclear. Additional integrin may provide
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ment to the basal lamina. This could be accomplished by increased
integrin-mediated adhesion and/or stabilization of components of the
dystrophin complex that are expressed but markedly reduced in the
plasma membrane in the absence of dystrophin. The preservation of
membrane structure and reduction in inﬂammation observed in
α7BX2-mdx/utr−/− mice [11] may slow the rapid onset of degener-
ation–regeneration cycles observed during the ﬁrst few weeks of
development, allowing differentiation and growth of ﬁbers to
dominate. Alternatively, the α7β1 integrin may initiate an orches-
trated series of signaling events inside the ﬁber that prevent apoptosis
[12,13], a more controlled method for reducing ﬁber number which
has been demonstrated in mdxmice [14]. ILK, the integrin-associated
kinase, and its downstream substrate, the anti-apoptotic protein
kinase B (PKB/AKT) appear to be important for the preservation of the
myotendinous junction, such that the absence of ILK decreases AKT
phosphorylation and leads to a milder form of muscular dystrophy in
mice [15] and decreased cardiomyocyte defects in mice and zebraﬁsh
[16,17]. A comparative evaluation of the signaling events taking place
in α7BX2-mdx/utr−/− versus mdx/utr−/− skeletal muscle provides an
important step in understanding the underlying mechanism of α7
integrin-driven protection during dystrophy.
The purpose of this study was to evaluate the activation and
expression of integrin-associated proteins that mediate cell signaling
in mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mouse skeletal muscle.
Elevations in ILK activity, ILK protein, and the AKT phosphorylation:
AKT ratio were observed inα7BX2-mdx/utr−/−mice compared tomdx
and mdx/utr−/− mice. The activation of this signaling pathway was
conﬁrmed through the parallel enhancement of p70S6K phosphory-
lation in α7BX2-mdx/utr−/− mice. p70S6K phosphorylation is asso-
ciated with increased initiation of protein translation necessary for
increased muscle growth. Bcl-2/Bcl-XL-associated death promoter
(BAD) phosphorylation and a concomitant decrease in apoptosis were
also observed in dystrophic mice expressing higher levels of the α7
integrin. In addition, speciﬁc association of ILK with a critical tyrosine
residue on the α7 integrin subunit is demonstrated. These results
reveal that increasing the amount of α7β1 integrin results in the
activation of the ILK–AKT signaling pathway which promotes cell
survival and hypertrophy and plays an important role in the integrin-
mediated rescue of α7BX2-mdx/utr−/− transgenic mice.
2. Materials and methods
2.1. Transgenic mice
The generation of transgenicmouse lines expressing the ratα7BX2
protein has been previously described [11]. Transgenic mdx/utr+/−
male mice were bred with mdx/utr+/− females to produce transgenic
α7BX2-mdx/utr−/− animals. Transgenic mice used in this study were
5 weeks of age and have an approximately 4-fold increase in α7BX2
protein in their hindlimb muscle compared to non-transgenic wild
type mice and a 2-fold increase over that detected inmdx/utr−/−mice
[11]. Procedures for animal use and care were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Illinois at Urbana-Champaign.
2.2. Antibodies
ILK polyclonal antibody was purchased from Santa Cruz Biotech-
nology, Santa Cruz, CA, for determination of total ILK expression. AKT,
phospho-AKT (Ser 473), phosphor-mTOR (Ser2448), mTOR, phospho-
p70S6K, p70S6K, phospho-BAD (Ser 112), BAD, ERK (Thr202/Tyr204),
ERK, phospho-p38 (Thr180/Tyr182), and p38 antibodies were
purchased from Cell Signaling Technology, Beverly, MA. HRP-labeled
donkey anti-mouse and anti-rabbit antibodies were purchased from
Jackson ImmunoResearch Laboratories Inc., West Grove, PA.2.3. ILK activity assay
Hindlimb muscles were powdered in liquid nitrogen using a mortar
and pestle. Proteins were extracted in ice-cold lysis buffer containing
2% Triton X-100, 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA (pH 8.0), 1 mM EGTA (pH 7.5), 2.5 mM Na pyrophosphate, 1 mM
β-glycerophosphate, 1 mM sodium vanadate, 1:200 protease inhibitor
cocktail III (Calbiochem), and 1 mM PMSF. Homogenates were rotated
30 min at 4 °C and centrifuged for 5 min at 10,000 g. Supernatants were
collected and protein concentrations were determined using Bradford
assays. Muscle extracts (1 mg) were precleared with 20 μL prewashed
protein G beads prior to immunoprecipitationwith 10 μL of ILK antibody
(Millipore [Upstate Biotechnology, 06-592], Billerica, MA) in a total
volume of 1 mL of fresh lysis buffer overnight at 4 °C, followed by the
addition of 20 μL protein G beads for 2 h. Supernatants were discarded
and beads were washed twice with lysis buffer and once with 2×
lysis buffer (62.5 mM MOPS (pH 7.5), 37.5 mM MgCl2, 2.5 mM EGTA,
0.1 M β-glycerophosphate, 0.1 M sodium ﬂuoride, 0.1 M sodium vana-
date, and 330 mM DTT) diluted 1:1. In vitro kinase buffer containing 2×
kinase buffer, 1 mg/mL basic myelin protein, and 10 μCi of adenosine
5′ triphosphate (γ-32P) (PerkinElmer, Boston, MA) was added to each
sample for 20 minat 30 °Cand the reactionwas terminatedwith10 μL4×
Laemmli buffer containing 330 mM DTT, followed by boiling for 5 min.
Samples were loaded onto a 12% gel for approximately 1 h at 200 V. Gels
were rinsed, stained with 1:1 fast green stain (Sigma), destained, and
then dried. Gelswere exposed in a PhosphoImager cassette for 1–2 h and
then bands were quantiﬁed using a PhosphoImager and Image Reader
software. Muscle samples were also run as negative controls without ILK
antibody or MBP to verify the validity of this assay.
2.4. ILK immunoprecipitation
Approximately 3×105 C2C12 mouse myoblasts, stably transfected
to express the α7BX2 integrin chain or a cytoplasmic domain mutant
α7BX2-YTF (tyrosine to phenylalanine mutation), were cultured on
ﬁbronectin-coated dishes in Dulbecco's medium (low glucose)
containing 20% fetal calf serum, 0.5% chicken embryo extract, 2 mM
glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin and
10 μg/mL kanamycin [19]. G418 was added to ensure selection of
stably transfected cells. At 80% conﬂuence, Dulbecco's medium
containing 2% horse serum (no embryo extract) was added to induce
differentiation. Association of ILK with the α7BX2 integrin was
induced by engaging the integrin with 15 μg/mL of puriﬁed anti-α7
(O26) antibody [18], a concentration that also induces acetylcholine
receptor clustering [19]. Following antibody stimulation, cells were
washed once in ice-cold phosphate buffered saline containing 2 mM
PMSF, collected and extracted in ice-cold lysis buffer as described
above for the ILK activity assay, except that 2% NP-40 was used in
place of Triton-X. The Bradford assay was used to determine protein
concentration. Protein extracts (0.5 g) were incubated overnight with
10 μL ILK antibody (Millipore [Upstate Biotechnology, 06-592]) and
incubated for 2 h with 20 μL prewashed protein G beads. The beads
were washed 3 times with NP-40 lysis buffer, boiled with 40 μL 2×
Laemmli buffer and samples were loaded onto 8% gels. Following
electrophoresis, proteins were transferred to nitrocellulose, blocked
with 5% BSA, and examined for α7BX2 using CDB antibody, reactive
with the cytoplasmic α7B cytoplasmic domain [20]. Blocking peptide
experiments veriﬁed the α7 integrin immunoreactive bands follow-
ing detection with secondary antibody and enhanced chemilumines-
cence (ECL) (Amersham Pharmacia Biotech, Piscataway, NJ).
2.5. PI3K activity assay
Extracts (2 mg) prepared from hindlimb muscles (as described for
the ILK activity assay above) were pre-cleared with 20 μL pre-cleared
protein G beads prior to immunoprecipitationwith 5 μL of p85 antibody
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volume of 1 mL of fresh lysis buffer overnight at 4 °C, followed by the
addition of 60 μL protein A beads for 2 h. Supernatants were discarded
and beads werewashed twicewith each of the following buffers: Buffer
1 [10×PBS, 1%NP-40, 100 μMsodiumvanadate], Buffer 2 [100 mMTris–
HCl (pH 7.5), 500 mM LiCl, 100 mM sodium vanadate], and Buffer 3
[10 mM Tris (pH 7.5), 100 mM NaCl, 100 mM sodium vanadate, and
1 mM EDTA]. Phosphatidylinositol (PI) substrate (10 μL; Aventi Polar
Lipids, Alabaster, AL) and 10 μL of 100 mM MgCl2 were added to each
tube prior to initiation of reaction with adenosine 5′ triphosphate (γ-
32P) (7 μCi/sample), 100 mMMgCl2, and ATP (10 mM; Sigma, A9187) at
30 °C for 30 min, vortexing every 2 min. The reactions were terminated
with20 μL8 NHCl. Lipidswere extracted ina 1:1 choloroform:methanol
and spotted onto thin layer chromatography plates (Silica gel 60A
plates, 250 μm layer thickness, Fisher Scientiﬁc). Migration of lipids
occurred by capillary action in a TLC tank and TLC plates were air dried
for 30 min and exposed to a PhosphoImager cassette. Lipids were
quantiﬁed using a PhosphoImager and Image Reader software.
Omission of antibody and substrate were used as controls.
2.6. Western analysis
Hindlimb muscles were powdered in liquid nitrogen using a mortar
and pestle. Extraction of proteins was completed at 4 °C in ice-cold lysis
buffer containing either 200 mMoctyl-β-D-glucopyranoside or 2% TritonFig. 1. Integrin-linked kinase (ILK) and PI3 kinase (PI3K) activities are increased in transgenic
MBP as a substrate inmuscle from5 week-oldwild type,mdx,mdx/utr−/−, andα7BX2-mdx/utr−
α7BX2-mdx/utr−/−micewith corresponding increases in ILK protein. (B) ILK associationwithα
cytoplasmic Tyr to Phe substitution (C2C12-α7BX2-YTF). ILKwas not bound toα7BX2 in the abs
(within 5 s) in its presence. Ab=antibody only lane. (C) Total PI3K activity was evaluated in 5
increased in both mdx/utr−/− and α7BX2-mdx/utr−/−mice (n=5–7/grp). *=vs. wild type anX-100 in 100 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2 mM PMSF, 1:200
dilution of Protease Cocktail Set III (Calbiochem, La Jolla, CA), 1 mMCaCl2,
and 1 mMMgCl2 at 4 °C for 1 h. Supernatants were collected and protein
concentrations were determined using Bradford assays. Equal amounts
of extracted muscle proteins were separated on 8–12% SDS polyacryl-
amide gels at 40 mA for 50 min. Proteins were transferred to nitrocel-
lulose membranes for 1 h at 100 V and membranes were stained with
Ponceau S (Sigma) to ensure equal protein loading. Membranes were
blocked in Tris-buffered saline (pH 7.8) containing 5% BSA and
membranes were incubated overnight with the following antibodies at
a concentration of 1:1000 unless otherwise indicated: ILK, phospho-AKT
(1:2000), AKT, phospho-mTOR, mTOR, phospho-p70S6K (1:500),
p70S6K (1:500), phospho-BAD, BAD, phospho-ERK, ERK, phospho-p38,
and p38. Anti-rabbit or anti-goat antibodies coupled with horseradish
peroxidase were used to detect primary antibodies (1:2000). Immuno-
reactive bands were detected using an enhanced chemiluminescence kit
(ECL) (Amersham Pharmacia Biotech, Piscataway, NJ). ImageQuant
software (Amersham Pharmacia Biotech) was used to measure the
intensities of immunoreactive bands on scanned ﬁlms and intensity of
the 43 kDa actin band on digital photos of Ponceau S-stained blots.
2.7. Apoptosis
Apoptotic nuclei were detected by using the DEAD END™
Fluorometric TUNEL System (Promega, Madison, WI). Brieﬂy,mice overexpressing the α7BX2 integrin. (A) ILK protein and activity were assessed using
/−mice (n=3–6/grp;mdx group n=3). ILK activitywas increased in bothmdx/utr−/− and
7BX2was examined in vitro in C2C12 cells transfectedwithα7BX2 orα7BX2 containing a
ence of stimulationwith anti-α7 antibody (O26) in control cells (C), but quickly associates
week-old wild type,mdx,mdx/utr−/−, and α7BX2-mdx/utr−/−mice. (D) PI3K activity was
d #=vs. mdx (Pb0.05).
Fig. 2. Total AKT and phosphorylated AKT are increased in α7BX2-mdx/utr−/− mice.
(A) AKT phosphorylation (Ser473) and expression were examined in 5 week-old wild
type, mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice (n=4–6/grp) and reported as a
percentage of an internal control sample. AKT expression is increased in all groups
compared to wild type, however, AKT phosphorylation was only signiﬁcantly increased
in α7BX2-mdx/utr−/−mice. (B) The ratio of phosphorylated to total expression of AKT
was measured. The α7BX2-mdx/utr−/− mice have higher proportions of activated AKT
compared to all other groups. *=vs. wild type, #=vs. mdx, and §=vs. all groups
(Pb0.05).
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at −80 °C until needed. Using a CM1900 series cryostat (Leica
Microsystems, Germany), 10 μm-thick sections were cut and put on
microscope slides. Multiple sections at least 50 μm apart were
obtained from each animal. Sections were treated as instructed
according to the DEAD END™ Fluorometric TUNEL System. Apoptotic
nuclei were scored by counting the total number of TUNEL+ nuclei per
50 40× ﬁelds.
2.8. Statistics
All averaged data are presented as the means±SE. Comparisons of
signaling and TUNEL staining between groups were performed by
one-way ANOVA, followed by Tukey's post hoc analysis (SigmaStat).
Differences were considered signiﬁcant at Pb0.05.
3. Results
3.1. Integrin linked kinase (ILK) associates with the α7 integrin and is
increased in the skeletal muscle of mice with elevated α7 integrin
Integrins have a dual functional capacity in cell adhesion and cell
signaling [21]. Therefore, increasing α7β1 integrin in skeletal muscle
may result in changes in cell signaling that could ameliorate the
development of dystrophic muscle. To investigate if altered cell
signaling played a role in the rescue ofmdx/utr−/−mice we examined
the expression and activity of candidate downstream integrin
signaling proteins in α7BX2-mdx/utr−/− mice.
Integrin linked kinase (ILK) is a serine/threonine protein kinase
that interacts with β1 integrin cytoplasmic domains and mediates
protein–protein interactions, cell signaling, and adhesion [22,23]. ILK
protein and activity were analyzed in 5 week-old mice with enhanced
levels of theα7β1 integrin. ILK activity wasmeasured by in vitro assay
using MBP as a substrate. Western blot analysis revealed signiﬁcant
increases in ILK protein in hindlimb ofmdx (2-fold),mdx/utr−/− (2.5-
fold) and α7BX2-mdx/utr−/− (2.9-fold) mice compared to wild type
animals (Fig. 1A). ILK activity was increased in mdx/utr−/− (2.0-fold)
and α7BX2-mdx/utr−/− (2.5-fold) mice compared to wild type
animals (Fig. 1A). ILK activity and expression were elevated but not
statistically higher in α7BX2-mdx/utr−/− compared to mdx-utr−/−
mice. Interestingly, the amount of ILK protein was increased 2.0-fold
in mdx mice yet ILK activity remained unchanged. The coincident
elevations in ILK and ILK activity in mice overexpressing the α7
integrin prompted us to examine whether ILK speciﬁcally associates
with the α7BX2 isoform. We evaluated this interaction using C2C12
myoblasts stably transfected with α7BX2 or a mutant form of α7BX2
(tyrosine to phenylalanine mutation). In the absence of activation of
the integrin with anti-α7 antibody (O26), ILK did not associate with
the integrin. However, stimulation with anti-α7 antibody resulted in
the rapid (5 s) phosphorylation of the α7BX2 integrin chain (data not
shown) and its association with ILK, an interaction that remained
stable for at least 1 min (Fig. 1B). Interestingly, both phosphorylation
and the association with ILK were suppressed in the absence of this
critical tyrosine residue.
Phosphoinositide-3-OH kinase (PI3K) appears to be important for
activationofdownstreamsignalingby ILK [24]. PI3Kwasnot activated in
mdx, yet increased in both mdx/utr−/− (47%) and α7BX2-mdx/utr−/−
(24%) compared towild type, consistent with our results for ILK activity
in these mice (Fig. 1C and D).
3.2. The AKT signaling pathway is enhanced by increased α7β1 integrin
The active form of AKT is phosphorylated and acts downstream from
ILK in a pathway that inhibits apoptosis and promotes cell survival
[24,25] via the anti-apoptotic protein BAD [26]. We have previously
reported resistance to apoptosis in C2C12 mouse myoblasts over-expressing the α7 integrin [12]. To further determine if integrin-
mediated anti-apoptotic signaling is enhanced in the transgenic animals,
the amount of phosphorylated and total AKT levels were measured in
extracts of hindlimb muscle from wild type, mdx, mdx/utr−/− and
α7BX2-mdx/utr−/−mice. Total AKT increased 2.4-fold, 3.9-fold, and 3.4-
fold in mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice, respectively,
compared towild type animals (Fig. 2A). A 6.3-fold increase in phospho-
AKT (Ser 473) was detected inmdx/utr−/−mice compared to wild type
animals and a 10-fold increase in phospho-AKT (Ser 473) was found in
α7BX2-mdx/utr−/−mice (Fig. 2A). No differences were observed in the
proportions of AKT that were active in wild type, mdx, or mdx/utr−/−
mice. In contrast,α7BX2-mdx/utr−/−mice have a signiﬁcant increase in
the proportion of active AKT compared to all the groups (Fig. 2B).
3.3. Increased α7β1 integrin results in reduced apoptosis in α7BX2-mdx/
utr−/− mice
Active AKT is pivotal in regulating proteins involved in cell survival,
growth, and muscle integrity, including the Bcl-2/Bcl-XL-associated
death promoter (BAD). Phosphorylation of pro-apoptotic BAD on
Ser136 or 112 results in loss of the ability of BAD to heterodimerize
with the survival proteins Bcl-XL or Bcl-2. Phosphorylated BAD then
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remains sequestered in the cytoplasm.This results in the loss of ability of
BAD to initiate apoptosis and thereby promotes cell survival. Phosphor-
ylation of BAD on Ser136, a preferred substrate for AKT, was not
detected in our samples using themethods described (data not shown),
despite conﬁrmation of BAD expression which was unaltered. On the
other hand, phosphorylation of BAD on Ser112 was increased 2.8-fold,
3.0-fold, and 5-fold in mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice,
respectively, compared to wild type animals (Fig. 3A). Similar to results
for ILK activity and expression, BAD Ser112 phosphorylation was
elevated but not signiﬁcantly higher inα7BX2-mdx/utr−/− compared to
mdx/utr−/−mice. ERK is an upstream regulator of BAD phosphorylation
on Ser112. Phosphorylation of ERK was elevated in all dystrophic mice
and correlated with levels of BAD Ser112 phosphorylation (Fig. 3B). No
changes in ERK protein were observed between groups.
The increase in BAD phosphorylation prompted us to examine
apoptosis in these mice. The number of TUNEL+ apoptotic nuclei was
not increased in mdxmice but was markedly increased inmdx/utr−/−
mice compared to wild type mice (Fig. 3C). Although still elevated
compared to wild type, the number of TUNEL+ nuclei was attenuated
in α7BX2-mdx/utr−/− mice compared to mdx/utr−/−. Thus, the
increased amount of α7β1 integrin may maintain muscle integrity
in α7BX2-mdx/utr−/− mice in part by preventing apoptosis.Fig. 3. Phosphorylation of BAD and ERK is increased and apoptosis is inhibited inα7BX2-mdx
mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice (n=4–8/grp) and reported as a percentage
α7BX2-mdx/utr−/− compared to wild type mice. Total BAD levels were unchanged (no
phosphorylationwas increased in all groups (n=4–8/grp). (C) TUNEL+nuclei were counted
andα7BX2-mdx/utr−/−mice (n=4–7/grp). A representative image of TUNEL staining is show
mdx, and apoptosis was suppressed in dystrophic mice expressing the α7 integrin transgen3.4. p70S6K is enhanced by increased α7β1 integrin
The serine kinase activity of AKT also promotes ﬁber growth by
activation of mTOR and p70S6K [27]. We previously reported a 4-fold
increase in hypertrophic ﬁbers in α7BX2-mdx/utr−/− compared tomdx/
utr−/−mice in both soleus and the tibialis anterior muscles [28]. While
total expression of mTOR and p70S6K were not altered in any group,
mTOR phosphorylation was increased (57%) in mdx/utr−/− mice
compared to wild type (Fig. 4A). mTOR phosphorylation was not altered
in α7BX2-mdx/utr−/− mice compared to any other group. Strikingly,
p70S6Kphosphorylationwas increased 6.7-fold, 11.7-fold, and 18-fold in
mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice, respectively, compared
towild type animals. p70S6Kphosphorylationwas signiﬁcantly higher in
α7BX-mdx/utr−/− compared to mdx/utr−/− mice (Fig. 4B). Together,
these data suggest that the AKT pathway is enhanced in severely
dystrophicmdx/utr−/−mice and that it is further activated by increased
integrin in α7BX2-mdx/utr−/− mice. This likely contributes to the
formation of hypertrophic ﬁbers previously observed in these animals.
3.5. Dystrophy decreases phosphorylation of p38
Reductions in p38 phosphorylation have been reported in
diaphragm muscle of mdx mice [29]. In this study, p38 levels were/utr−/−mice. (A) BAD phosphorylation (Ser112) was examined in 5 week-old wild type,
of an internal control sample. BAD phosphorylation was signiﬁcantly increased only in
t shown). (B) ERK is an upstream regulator of BAD Ser112 phosphorylation. ERK
as an indication of apoptosis in skeletalmuscle of 5 week-oldwild type,mdx,mdx/utr−/−,
n. Apoptosis was signiﬁcantly increased inmdx/utr−/−mice compared to wild type and
e. *=vs. wild type, #=vs. mdx, and §=vs. all groups (Pb0.05).
Fig. 4. Signaling associated with muscle hypertrophy is activated in α7BX2-mdx/utr−/−
mice. mTOR and p70S6K phosphorylation were measured in muscle from 5 week-old
wild type, mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice (4–6/grp). (A) mTOR
phosphorylation was signiﬁcantly increased only in α7BX2-mdx/utr−/− muscle
compared to wild type mice. (B) p70S6K phosphorylation was signiﬁcantly increased
in all groups compared to wild type muscle, and was higher in α7BX2-mdx/utr−/−mice
compared to mdx/utr−/− mice that did not express the transgene. *=vs. wild type,
#=vs. mdx, and ^=vs. mdx/utr−/− (Pb0.05).
Fig. 5. p38 phosphorylation is reduced in dystrophic mice and increasing α7 integrin
did not restore activation. p38 phosphorylation was measured in muscle from 5 week-
old wild type, mdx, mdx/utr−/−, and α7BX2-mdx/utr−/− mice (n=4–6). p38
phosphorylation was decreased to the same extent in all mice evaluated. *=vs. wild
type (Pb0.05).
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signiﬁcantly decreased in hindlimb muscle to the same extent in all
dystrophic mice examined (Fig. 5). The signiﬁcance of p38 suppres-
sion in the dystrophic mice is not clear, but the level of α7 integrin in
muscle does not seem to inﬂuence p38 activity.
4. Discussion
Duchenne muscular dystrophy (DMD) is an X-linked human
disease affecting 1/3500 newborn boys. Mutations in the dystrophin
gene result in a lack of the dystrophin protein in both patients and
mdx mice. The loss of dystrophin leads to a breakdown of a
transmembrane system linking laminin in the extracellular matrix
to the actin cytoskeleton resulting in muscle disease. Attempts to treat
muscular dystrophy have involved both direct gene replacement andgene repair [30–32]. Recently, several additional approaches have
emerged based on the study of proteins with complementary
functions to the dystrophin glycoprotein complex [11,33]. The α7β1
integrin is a laminin receptor on the surface of muscle cells that
interacts with the actin cytoskeleton and has complementary
functions to the dystrophin glycoprotein complex. Enhanced expres-
sion of the α7β1 integrin in mice lacking dystrophin and utrophin
results in a three-fold increase in life span and partial rescue of muscle
pathology in mice that would normally develop severe muscle disease
and die [11]. The mechanisms by which enhanced levels of the α7β1
integrin rescued these mice are unclear and have been the focus of
this investigation.
The α7 integrin and ILK are localized to similar structures in
muscle, including costameres and myotendinous junctions [15,34].
Previous groups reported binding of ILK with the β1 integrin subunit
and this association results in the activation of AKT in vitro [24,35,36].
Loss of either the α7 integrin or ILK independently results in mild
muscular dystrophies characterized by progressive loss of integrity at
myotendinous and neuromuscular junctions that worsens with age or
mechanical stress [15,37]. In this paper, we show that the amount of
ILK protein and activity are increased in bothmdx/utr−/− and α7BX2-
mdx/utr−/− compared to wild type and mdx mice. Although ILK
activity is not signiﬁcantly higher in α7BX2-mdx/utr−/− compared to
mdx/utr−/−, an elevation in activation is observed. Interestingly,
association of ILK with the α7BX2 integrin subunit upon stimulation
with an anti-α7 integrin antibody was observed in vitro. Thus,
engagement of the α7 integrin in vivo may facilitate ILK binding and
allow ILK to stably interact with proteins at focal adhesions within the
sarcolemma. Although we did not evaluate binding between α7 and
ILK in vivo, it is tempting to speculate that ﬁbrosis associated with
dystrophy prevents the α7 integrin–laminin interaction necessary for
α7 integrin activation, ILK binding to the α7 integrin, and concom-
itant initiation of anti-apoptotic and regenerative signaling. We have
previously demonstrated the ability of the α7 integrin transgene to
decrease inﬂammation and improve the microenvironment in
α7BX2-mdx/utr−/− mice [11,28]. These beneﬁcial changes may
facilitate greater adhesion of the α7 integrin with the laminin matrix
and subsequently activate the ILK survival pathway (Fig. 6). In
addition, elimination of α7 integrin in mdxmice (α7/mdx−/−) results
in severe muscle disease that may in part result from loss of integrin-
mediated ILK activation [38].
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α7β1 
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Cell Survival
BAD
Apoptosis
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Fig. 6. Signaling pathways by which the α7 integrin decreases pathology in dystrophic
mice. The α7 integrin–ILK complex is activated in response to extracellular matrix
attachment, resulting in phosphorylation of AKT and p70S6K in anmTOR-dependent or
independent manner, resulting in increased muscle growth. The α7–ILK complex may
also stimulate phosphorylation of BAD on Ser112 (via ERK), suppressing the pro-
apoptotic actions of BAD and enhancing cell survival.
445M.D. Boppart et al. / Biochimica et Biophysica Acta 1812 (2011) 439–446An increase in the level of apoptosis has been reported in mdx
mice, suggesting programmed cell death plays a role in the pathology
underlyingmuscular dystrophy [14]. Since theα7β1 integrin has been
implicated in muscle cell survival [10–13,39], increased transgenic
expression of α7β1 integrin may inhibit apoptosis in mice that would
normally develop severe muscular dystrophy. We have previously
reported that overexpression of theα7 integrin transgene can prevent
staurosporine-induced apoptosis in C2C12 myoblasts in culture [12].
In this study, expression of the α7 integrin transgene did suppress
apoptosis in α7BX2-mdx/utr−/− mice compared to mdx/utr−/− mice.
Inhibition of the pro-apoptotic BAD by AKT-mediated phosphoryla-
tion on Ser136 is important for limiting cell death, presumably by
allowing association of BAD with 14-3-3 which sequesters it in the
cytoplasm. We did not detect BAD phosphorylation at Ser136, but
phosphorylation at Ser112 was enhanced in α7BX2-mdx/utr−/−mice,
perhaps due to ERK which strongly inﬂuences phosphorylation at this
site [40,41]. Since Ser112 phosphorylation is also important for
inhibiting the pro-apoptotic function of BAD [26], it is likely this
signaling event played a signiﬁcant role in the suppression of
apoptosis and protection from developing pathology in mice over-
expressing the α7 integrin transgene. Further studies of α7 integrin-
mediated regulation of the apoptotic signaling pathway in muscle are
warranted.
In addition to promoting cell survival, AKT is a key regulator of the
compensatory hypertrophy that is a hallmark of muscular dystrophy.
AKT phosphorylation and expression are consistently activated in
both diaphragm [42] and skeletal muscle [43,44] in mouse models of
disease and in patients with muscular dystrophy. Moreover, condi-
tional overexpression of muscle-speciﬁc AKT can enhance muscle
mass and ﬁber cross-sectional area in mdx mice [45]. p70S6K, an
initiator of protein translation, lies downstream within the AKT
signaling pathway and is upregulated in mdx hindlimb [43] and
diaphragm muscles [29]. Consistent with these ﬁndings, hypertrophy
is increased in hindlimbs of α7BX2-mdx/utr−/− mice compared toboth wild type and mdx/utr−/− mice [28]. In this study, we report a
marked increase in p70S6K phosphorylation in severely dystrophic
α7BX2-mdx/utr−/− mice that overexpress the α7 integrin transgene
compared to mice that do not. Although mTOR phosphorylation was
not elevated to the same extent in these mice, it is possible that AKT
activates p70S6K independently of mTOR or perhaps p70S6K is
directly activated by the integrin via amechanoregulatorymechanism
as a result of enhanced adhesion to the surrounding basal lamina.
Amino acid uptake and protein synthesis can occur in cultured
myotubes in the complete absence of systemic factors as a result of
stretch, yet the mechanism responsible for this hypertrophic effect is
still not known [46]. Our data suggest that p70S6Kmay be activated as
a result of increased α7 integrin and this event contributes to
hypertrophic responses necessary to combat loss of myoﬁbrillar
proteins and disease progression.
p38 is a member of the mitogen-activated protein kinase family
that is ubiquitously expressed in a variety of tissues and activated by
stressors, such as proinﬂammatory cytokines, osmotic shock, shear
stress, and stretch [47,48]. Although the precise role of p38 in skeletal
muscle is not clear, p38 has been suggested to positively inﬂuence
myogenic cell differentiation [48] and mitochondrial biosynthesis
[49,50], and it plays a protective role against apoptosis [51] and
Foxo3a-induced muscle atrophy [52]. In this study, we observe a
consistent decline in p38 phosphorylation in all models of muscular
dystrophy, including mice overexpressing the α7 integrin. These
results are similar to several studies that report signiﬁcant decreases
in p38 phosphorylation in dystrophic diaphragm and hindlimb
muscle [29,53,54]. We were surprised that increasing the amount of
α7 integrin did not restore p38 phosphorylation levels given our
previous data showed elevated activation of p38 3 h following
exercise in mice overexpressing the α7 integrin in wild type mice
[55].
This study reveals for the ﬁrst time that the α7β1 integrin plays an
important role in modulating the activation of several signaling
molecules important for promoting muscle cell survival and hyper-
trophy in mice with severe muscular dystrophy. Elevated expression
and activation of the α7β1 integrin or molecules in its pathway may
provide novel avenues for treatment of neuromuscular diseases.
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